These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 14659985)

  • 1. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia.
    Bozikas VP; Papakosta M; Niopas I; Karavatos A; Mirtsou-Fidani V
    Eur Neuropsychopharmacol; 2004 Jan; 14(1):39-44. PubMed ID: 14659985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
    Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
    Carrillo JA; Christensen M; Ramos SI; Alm C; Dahl ML; Benitez J; Bertilsson L
    Ther Drug Monit; 2000 Aug; 22(4):409-17. PubMed ID: 10942180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
    Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
    J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
    Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
    Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
    Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
    Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity.
    Sinués B; Fanlo A; Bernal ML; Mayayo E; Soriano MA; Martínez-Ballarin E
    Ther Drug Monit; 2002 Dec; 24(6):715-21. PubMed ID: 12451287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
    Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
    J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
    Krul C; Hageman G
    J Chromatogr B Biomed Sci Appl; 1998 May; 709(1):27-34. PubMed ID: 9653923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.
    Gunes A; Ozbey G; Vural EH; Uluoglu C; Scordo MG; Zengil H; Dahl ML
    Pharmacogenomics; 2009 May; 10(5):769-78. PubMed ID: 19450128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caffeine metabolism before and after liver transplantation.
    Bechtel YC; Lelouët H; Hrusovsky S; Brientini MP; Mantion G; Paintaud G; Miguet JP; Bechtel PR
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):53-60. PubMed ID: 11270802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary effects of Sideritis scardica "mountain tea" on human in vivo activities of xenobiotic metabolizing enzymes in healthy subjects.
    Begas E; Kilindris T; Kouvaras E; Tsioutsioumi A; Kouretas D; Asprodini EK
    Food Chem Toxicol; 2018 Dec; 122():38-48. PubMed ID: 30266316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism.
    Chung WG; Kang JH; Park CS; Cho MH; Cha YN
    Clin Pharmacol Ther; 2000 Mar; 67(3):258-66. PubMed ID: 10741629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.
    Relling MV; Lin JS; Ayers GD; Evans WE
    Clin Pharmacol Ther; 1992 Dec; 52(6):643-58. PubMed ID: 1458773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP1A2 in a smoking and a non-smoking population; correlation of urinary and salivary phenotypic ratios.
    Woolridge H; Williams J; Cronin A; Evans N; Steventon GB
    Drug Metabol Drug Interact; 2004; 20(4):247-61. PubMed ID: 15663294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.
    Rasmussen BB; Brøsen K
    Ther Drug Monit; 1996 Jun; 18(3):254-62. PubMed ID: 8738764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.
    Nyéki A; Buclin T; Biollaz J; Decosterd LA
    Br J Clin Pharmacol; 2003 Jan; 55(1):62-7. PubMed ID: 12534641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population and family study of CYP1A2 using caffeine urinary metabolites.
    Catteau A; Bechtel YC; Poisson N; Bechtel PR; Bonaïti-Pellie C
    Eur J Clin Pharmacol; 1995; 47(5):423-30. PubMed ID: 7720764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
    Hakooz NM
    Curr Drug Metab; 2009 May; 10(4):329-38. PubMed ID: 19519341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered activity of xenobiotic detoxifying enzymes at menopause - A cross-sectional study.
    Tsiokou V; Kilindris T; Begas E; Kouvaras E; Kouretas D; Asprodini EK
    Environ Res; 2020 Mar; 182():109074. PubMed ID: 31923849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.